CMPS
COMPASS Pathways plc
NASDAQ · Healthcare · Medical - Care Facilities · GB
$13.27
−0.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 109.0M | 118.4M | 119.0M | 87.5M | 65.1M |
| SG&A Expense | 68.9M | 60.6M | 59.2M | 49.4M | 45.4M |
| General & Admin Expense | 68.9M | 60.6M | 59.2M | 49.4M | 45.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 3.9M | — | — | — | — |
| Total Operating Expenses | 181.8M | 179.0M | 178.2M | 136.9M | 110.4M |
| Cost and Expenses | 181.8M | 179.0M | 178.2M | 136.9M | 110.4M |
| Operating Income (EBIT) | (181.8M) | (179.0M) | (178.2M) | (136.9M) | (110.4M) |
| Non-Operating | |||||
| Interest Income | 9.0M | 7.2M | 8.3M | 4.6M | — |
| Interest Expense | 5.2M | 4.5M | 4.5M | 2.2M | — |
| Net Interest Income | 3.9M | 2.7M | 3.8M | 2.4M | — |
| Other Non-Op Income/Expense | (215.1M) | (111.3M) | 24.7M | 19.2M | 19.3M |
| Non-Operating Income (excl Interest) | 209.9M | 106.8M | (29.2M) | (21.4M) | (19.3M) |
| EBT (Pre-Tax Income) | (396.8M) | (290.3M) | (153.5M) | (117.7M) | (91.1M) |
| Income Tax Expense | (2.6M) | (2.5M) | 1.6M | 780.0K | 408.0K |
| Bottom Line | |||||
| Net Income | (394.2M) | (287.9M) | (155.1M) | (118.5M) | (91.5M) |
| Earnings from Cont. Ops | (394.2M) | (287.9M) | (155.1M) | (118.5M) | (91.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (525.1M) | (287.9M) | (155.1M) | (118.5M) | (91.5M) |
| Per Share | |||||
| Basic EPS | ($5.57) | ($3.08) | ($2.30) | ($2.32) | ($2.16) |
| Diluted EPS | ($5.57) | ($3.08) | ($2.30) | ($2.32) | ($2.16) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 93.6M | 93.5M | 67.5M | 51.0M | 42.4M |
| Diluted Shares Outstanding | 93.6M | 93.5M | 67.5M | 51.0M | 42.4M |
| Profitability Metrics | |||||
| EBITDA | (391.6M) | (285.6M) | (148.8M) | (115.2M) | (90.8M) |
| D&A | 75.0K | 216.0K | 233.0K | 242.0K | 330.0K |
| EBIT | (391.6M) | (285.8M) | (149.0M) | (115.5M) | (91.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026